Androgen-Responsive Genes in Prostate Cancer

pp 135-153


Androgen-Responsive Gene Expression in Prostate Cancer Progression

  • Amy H. TienAffiliated withGenome Sciences Centre, BC Cancer Agency
  • , Marianne D. SadarAffiliated withGenome Sciences Centre, BC Cancer Agency Email author 

* Final gross prices may vary according to local VAT.

Get Access


Benign and cancerous prostate tissue is dependent upon androgens. Androgen ablation causes prostate tissue to undergo apoptosis which thereby provides the rationale of castration as a systemic therapy for advanced prostate cancer. The full-length androgen receptor is a ligand-activated transcription factor that regulates the expression of genes required for growth, function, and survival of prostate cells in response to androgen. Androgen binds to the androgen receptor which then translocates to the nucleus to bind to androgen response elements on target genes termed “androgen-responsive genes” (ARGs) to regulate their transcription and levels of expression. Identification and characterization of ARGs may provide an understanding of androgen receptor signaling, resistance mechanisms to current hormonal therapies, and reveal biomarkers for patient selection and sequential application of current and new therapies targeting the androgen axis. This review addresses differential expression of ARGs following androgen ablation treatment during progression of advanced prostate cancer.


Androgen-responsive gene Prostate cancer Androgen receptor Castration-resistant prostate cancer (CRPC) Gene expression